Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings : Results From a Multi-Center International Study
Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved..
INTRODUCTION: This study assessed treatment discontinuation patterns and reasons among chronic lymphocytic leukemia (CLL) patients initiating first-line (1L) and second-line (2L) treatments in real-world settings.
MATERIALS AND METHODS: Using deidentified electronic medical records from the CLL Collaborative Study of Real-World Evidence, premature treatment discontinuation was assessed among FCR, BR, BTKi-based, and BCL-2-based regimen cohorts.
RESULTS: Of 1364 1L patients (initiated in 1997-2021), 190/13.9% received FCR (23.7% discontinued prematurely); 255/18.7% received BR (34.5% discontinued prematurely); 473/34.7% received BTKi-based regimens, of whom 28.1% discontinued prematurely; and 43/3.2% received venetoclax-based regimens, of whom 16.3% discontinued prematurely (venetoclax monotherapy: 7/0.5%, of whom 42.9% discontinued; VG/VR: 36/2.6%, of whom 11.1% discontinued). The most common reasons for treatment discontinuation were adverse events (FCR: 25/13.2%; BR: 36/14.1%; BTKi-based regimens: 75/15.9%) and disease progression (venetoclax-based: 3/7.0%). Of 626 2L patients, 20/3.2% received FCR (50.0% discontinued); 62/9.9% received BR (35.5% discontinued); 303/48.4% received BTKi-based regimens, of whom 38.0% discontinued; and 73/11.7% received venetoclax-based regimens, of whom 30.1% discontinued (venetoclax monotherapy: 27/4.3%, of whom 29.6% discontinued; VG/VR: 43/6.9%, of whom 27.9% discontinued). The most common reasons for treatment discontinuation were adverse events (FCR: 6/30.0%; BR: 11/17.7%; BTKi-based regimens: 60/19.8%; venetoclax-based: 6/8.2%).
CONCLUSION: The findings of this study highlight the continued need for tolerable therapies in CLL, with finite therapy offering a better tolerated option for patients who are newly diagnosed or relapsed/refractory to prior treatments.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Clinical lymphoma, myeloma & leukemia - 23(2023), 7 vom: 23. Juli, Seite 515-526 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shadman, Mazyar [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 20.06.2023 Date Revised 22.06.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.clml.2023.03.010 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355801957 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355801957 | ||
| 003 | DE-627 | ||
| 005 | 20231226065118.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.clml.2023.03.010 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1185.xml |
| 035 | |a (DE-627)NLM355801957 | ||
| 035 | |a (NLM)37076367 | ||
| 035 | |a (PII)S2152-2650(23)00107-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shadman, Mazyar |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings |b Results From a Multi-Center International Study |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.06.2023 | ||
| 500 | |a Date Revised 22.06.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved. | ||
| 520 | |a INTRODUCTION: This study assessed treatment discontinuation patterns and reasons among chronic lymphocytic leukemia (CLL) patients initiating first-line (1L) and second-line (2L) treatments in real-world settings | ||
| 520 | |a MATERIALS AND METHODS: Using deidentified electronic medical records from the CLL Collaborative Study of Real-World Evidence, premature treatment discontinuation was assessed among FCR, BR, BTKi-based, and BCL-2-based regimen cohorts | ||
| 520 | |a RESULTS: Of 1364 1L patients (initiated in 1997-2021), 190/13.9% received FCR (23.7% discontinued prematurely); 255/18.7% received BR (34.5% discontinued prematurely); 473/34.7% received BTKi-based regimens, of whom 28.1% discontinued prematurely; and 43/3.2% received venetoclax-based regimens, of whom 16.3% discontinued prematurely (venetoclax monotherapy: 7/0.5%, of whom 42.9% discontinued; VG/VR: 36/2.6%, of whom 11.1% discontinued). The most common reasons for treatment discontinuation were adverse events (FCR: 25/13.2%; BR: 36/14.1%; BTKi-based regimens: 75/15.9%) and disease progression (venetoclax-based: 3/7.0%). Of 626 2L patients, 20/3.2% received FCR (50.0% discontinued); 62/9.9% received BR (35.5% discontinued); 303/48.4% received BTKi-based regimens, of whom 38.0% discontinued; and 73/11.7% received venetoclax-based regimens, of whom 30.1% discontinued (venetoclax monotherapy: 27/4.3%, of whom 29.6% discontinued; VG/VR: 43/6.9%, of whom 27.9% discontinued). The most common reasons for treatment discontinuation were adverse events (FCR: 6/30.0%; BR: 11/17.7%; BTKi-based regimens: 60/19.8%; venetoclax-based: 6/8.2%) | ||
| 520 | |a CONCLUSION: The findings of this study highlight the continued need for tolerable therapies in CLL, with finite therapy offering a better tolerated option for patients who are newly diagnosed or relapsed/refractory to prior treatments | ||
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Adverse events | |
| 650 | 4 | |a Chemoimmunotherapy | |
| 650 | 4 | |a Chemotherapy | |
| 650 | 4 | |a Disease progression | |
| 650 | 4 | |a Targeted agents | |
| 650 | 7 | |a venetoclax |2 NLM | |
| 650 | 7 | |a N54AIC43PW |2 NLM | |
| 650 | 7 | |a Bridged Bicyclo Compounds, Heterocyclic |2 NLM | |
| 650 | 7 | |a Sulfonamides |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 700 | 1 | |a Manzoor, Beenish S |e verfasserin |4 aut | |
| 700 | 1 | |a Sail, Kavita |e verfasserin |4 aut | |
| 700 | 1 | |a Tuncer, Hande H |e verfasserin |4 aut | |
| 700 | 1 | |a Allan, John N |e verfasserin |4 aut | |
| 700 | 1 | |a Ujjani, Chaitra |e verfasserin |4 aut | |
| 700 | 1 | |a Emechebe, Nnadozie |e verfasserin |4 aut | |
| 700 | 1 | |a Kamalakar, Rajesh |e verfasserin |4 aut | |
| 700 | 1 | |a Coombs, Catherine C |e verfasserin |4 aut | |
| 700 | 1 | |a Leslie, Lori |e verfasserin |4 aut | |
| 700 | 1 | |a Barr, Paul M |e verfasserin |4 aut | |
| 700 | 1 | |a Brown, Jennifer R |e verfasserin |4 aut | |
| 700 | 1 | |a Eyre, Toby A |e verfasserin |4 aut | |
| 700 | 1 | |a Rampotas, Alexandros |e verfasserin |4 aut | |
| 700 | 1 | |a Schuh, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Lamanna, Nicole |e verfasserin |4 aut | |
| 700 | 1 | |a Skarbnik, Alan |e verfasserin |4 aut | |
| 700 | 1 | |a Roeker, Lindsey E |e verfasserin |4 aut | |
| 700 | 1 | |a Bannerji, Rajat |e verfasserin |4 aut | |
| 700 | 1 | |a Eichhorst, Barbara |e verfasserin |4 aut | |
| 700 | 1 | |a Fleury, Isabelle |e verfasserin |4 aut | |
| 700 | 1 | |a Davids, Matthew S |e verfasserin |4 aut | |
| 700 | 1 | |a Alhasani, Hasan |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Dingfeng |e verfasserin |4 aut | |
| 700 | 1 | |a Hill, Brian T |e verfasserin |4 aut | |
| 700 | 1 | |a Schuster, Stephen J |e verfasserin |4 aut | |
| 700 | 1 | |a Brander, Danielle M |e verfasserin |4 aut | |
| 700 | 1 | |a Pivneva, Irina |e verfasserin |4 aut | |
| 700 | 1 | |a Burne, Rebecca |e verfasserin |4 aut | |
| 700 | 1 | |a Guerin, Annie |e verfasserin |4 aut | |
| 700 | 1 | |a Mato, Anthony R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical lymphoma, myeloma & leukemia |d 2010 |g 23(2023), 7 vom: 23. Juli, Seite 515-526 |w (DE-627)NLM195738748 |x 2152-2669 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2023 |g number:7 |g day:23 |g month:07 |g pages:515-526 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.clml.2023.03.010 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2023 |e 7 |b 23 |c 07 |h 515-526 | ||